Altogether, the previous findings allow us to postulate the use of SHP1 and SHP2 inhibitors either alone or in combination with natural phorbol esters as a therapeutic strategy against non-APL AML. This evidence concerns the gene PTPN11 and acute promyelocytic leukemia.